openPR Logo
Press release

Leishmaniasis Treatment Market, By Disease Type, and Drug Type

07-10-2018 02:30 PM CET | Health & Medicine

Press release from: Pharmaceutical Report

Leishmaniasis Treatment Market, By Disease Type, and Drug Type

Leishmaniasis is parasitic disease caused due to an infection with Leishmania parasites and transmitted through the bite of infected female phlebotomine sand flies. According to the World Health Organization (WHO), approximately 7, 00,000 to 1 million new cases and 20,000 - 30,000 deaths occur worldwide annually due to the leishmaniasis. There are three forms of leishmaniasis namely mucocutaneous leishmaniasis, visceral leishmaniasis, and cutaneous leishmaniasis.

Visceral leishmaniasis (VL) is the most serious condition among the other two forms of leishmaniasis. According to the World Health Organization (WHO), about 50,000 to 90,000 new cases of visceral leishmaniasis occur worldwide annually. According to the WHO, in 2015, more than 90% of the new cases of visceral leishmaniasis were from Kenya, Somalia, Ethiopia, India, Brazil, Sudan, and South Sudan creating higher opportunity for leishmaniasis treatment market. The prevalence of cutaneous leishmaniasis in the North and South America, the Middle East, Central Asia, and Mediterranean basin is approximately 95%, according to the WHO April 2017 factsheet. People with leishmaniasis infection develop several symptoms, such as fever, weight loss, sores on skin, nose, mouth or throat, enlargement of spleen and liver, and abnormal blood tests. Some patients show symptoms of anemia, leukopenia, and thrombocytopenia. Geriatric population, infants, pregnant or lactating women, and HIV infected people have a high risk of acquiring leishmaniasis infections, due to their weak immune systems.

Click To Continue Reading:
https://www.coherentmarketinsights.com/ongoing-insight/leishmaniasis-treatment-market-932

Leishmaniasis disease transmission is mostly associated with unhygienic conditions, weak immune system, and malnutrition. Increasing climatic changes and population mobility are other risk factors associated with the leishmaniasis disease.

Depending on the degree of virulence and clinical preferences, the disease is characterized on the basis of the type of species and subspecies of leishmania parasite. The clinical pattern of disease, the geographic regions, and the immunological status of the patient are considered in leishmaniasis treatment. Multiple medical treatment options are available for treatment of cutaneous leishmaniasis, which includes parenteral and oral medications, infiltration of sodium stibogluconate at 0.3-0.8 ml, cryotherapy, local heat therapy at 40-420C, and topical paromomycin preparations. Leishmaniasis can be prevented by treating malnutrition, recurrent systemic infection or local infection. Tailored disease management for treating leishmaniasis is expected to have a potential for improving leishmaniasis treatment market in near future.

Download The PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/932

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: https://www.coherenttimes.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Leishmaniasis Treatment Market, By Disease Type, and Drug Type here

News-ID: 1118434 • Views:

More Releases from Pharmaceutical Report

Pharmaceutical Robots Market Forecast 2018- 2026: Kawasaki Heavy Industries,
Pharmaceutical Robots Market Forecast 2018- 2026: Kawasaki Heavy Industries,
Kawasaki Heavy Industries Ltd. (Japan), FANUC Corporation (Japan), KUKA AG (Germany), Mitsubishi Electric Corporation (Japan), ABB Ltd. (Switzerland), Denso Corporation (Japan), Seiko Epson Corporation (Japan), Marchesini Group S.p.A (Italy), Universal Robots A/S (Denmark), Kawasaki Heavy Industries ,Yaskawa Electric Corporation (Japan), and Shibuya Corporation (Japan) are the prominent players in the global pharmaceutical robots market. The global pharmaceutical robots market is anticipated to reach 452.7 million by 2025 and estimated to reach
Grow Owning to Innovations In Oncology Nutrition Market
Grow Owning to Innovations In Oncology Nutrition Market
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
FMD Vaccine Market - Shield against Economic Loss
FMD Vaccine Market - Shield against Economic Loss
Foot and Mouth Disease (FMD) causes repetitive outbreak around world thereby causing economic and social damage. Preventing foot and mouth disease is the only sustainable and viable options, which can be done only though the vaccination for FMD, which is expected to drive growth of the foot and mouth disease vaccine market. According to paper published by the Food and Agricultural Organization (FAO) and World Organization for Animal Health (OIE),
Divalproex Sodium Market Competitive Landscape,Regional Insights
Divalproex Sodium Market Competitive Landscape,Regional Insights
Increasing prevalence of bipolar disorders around the globe is propelling the divalproex sodium market growth. For instance, according to study published in JAMA Psychiatry Journal 2012, in a combined sample of 61,392 adults from 11 countries, the total lifetime prevalence of bipolar disorder-I was 0.6%, and 0.4% for bipolar disorder-II and subthreshold bipolar disorder was 1.4%, yielding a total prevalence estimates bipolar disorder spectrum of 2.4% globally. Moreover, rising patient pool

All 5 Releases


More Releases for Leishmania

Leishmaniasis Treatment Market Outlook 2021-2027- Sales Revenue, Industry Growt …
The global market for leishmaniasis therapy can be divided into three categories: drug type, diagnostic method, and vector control method. Leishmaniasis is a parasitic disease caused by Leishmania. The Leishmania parasite is a single-celled protozoan that is spread through the bite of an infected female phlebotomine sand fly. Use of nets or mesh, sprays, and pesticides effective against sandflies are all examples of market segmentation by vector control strategies. Leishmaniasis Treatment
Leishmaniasis Treatment Market to Witness Robust Expansion Throughout the Foreca …
Leishmaniasis is parasitic disease caused due to an infection with Leishmania parasites and transmitted through the bite of infected female phlebotomine sand flies. According to the World Health Organization (WHO), approximately 7, 00,000 to 1 million new cases and 20,000 - 30,000 deaths occur worldwide annually due to the leishmaniasis. There are three forms of leishmaniasis namely mucocutaneous leishmaniasis, visceral leishmaniasis, and cutaneous leishmaniasis. Visceral leishmaniasis (VL) is the most
Leishmaniasis Treatment Market Poised for Steady Growth in the Future
Leishmaniasis is a disease caused by the Leishmania parasites. The Leishmania parasite is a single cell protozoan, which is transmitted by the bite of the female phlebotomine sand fly infected by the parasite. There are over 20 Leishmania species reported, which are transmitted to humans by the bite of infected female phlebotomine sandflies. Furthermore, over 90 sand-fly species are known to transmit Leishmania parasites. Leishmaniasis consists of three different forms:
Market Research on Leishmaniasis Treatment Market 2017 and Analysis to 2025
Leishmaniasis is a disease caused by the Leishmania parasites. The Leishmania parasite is a single cell protozoan, which is transmitted by the bite of the female phlebotomine sand fly infected by the parasite. There are over 20 Leishmania species reported, which are transmitted to humans by the bite of infected female phlebotomine sandflies. Furthermore, over 90 sand-fly species are known to transmit Leishmania parasites. Leishmaniasis consists of three different forms:
Leishmaniasis Treatment Market - Industrial applications witness fastest growth …
Leishmaniasis is a disease caused by the Leishmania parasites. The Leishmania parasite is a single cell protozoan, which is transmitted by the bite of the female phlebotomine sand fly infected by the parasite. There are over 20 Leishmania species reported, which are transmitted to humans by the bite of infected female phlebotomine sandflies. Furthermore, over 90 sand-fly species are known to transmit Leishmania parasites. Leishmaniasis consists of three different forms:
Leishmaniasis Treatment Market Volume Forecast and Value Chain Analysis 2017-202 …
Leishmaniasis is a disease caused by the Leishmania parasites. The Leishmania parasite is a single cell protozoan, which is transmitted by the bite of the female phlebotomine sand fly infected by the parasite. There are over 20 Leishmania species reported, which are transmitted to humans by the bite of infected female phlebotomine sandflies. Furthermore, over 90 sand-fly species are known to transmit Leishmania parasites. Leishmaniasis consists of three different forms: visceral Leishmaniasis, cutaneous Leishmaniasis, and mucocutaneous